摘要
目的探讨低分子肝素在急性肺栓塞患者抗凝治疗中的疗效及安全性。方法对我院确诊的60例急性肺栓塞患者进行低分子肝素抗凝治疗,观察临床疗效及安全性。结果 60例肺栓塞患者经抗凝治疗后治愈48例,显效8例,死亡4例,总病死率为6.7%,出血并发症发生率为5%,再发肺栓塞2例。结论肺栓塞患者应用低分子肝素抗凝治疗副作用低,疗效可靠,可作为抗凝治疗的首选。
Objective To investigate the efficacy and safety of low molecular weight heparin of anticoagulation treatment in patients with acute pulmonary embolism. Methods 60 cases of patients with acute pulmonary embolism in our hospital diagnosed with low molecular weight heparin anticoagulant therapy, to observe the clinical efficacy and safety. Results 60 cases of patients with pulmonary embolism by anticoagulant therapy to cure 48 cases, markedly effective in 8 cases, 4 cases died, the total mortality was 6.7%, the incidence of bleeding complications was 5%, recurrence of 2 cases of pulmonary embolism. Conclusion The application of low molecular weight heparin in treatment of pulmonary embolism in the patients with low side effect, curative effect is reliable, can be used as the preferred anticoagulant therapy.
出处
《中国医药科学》
2015年第19期94-96,共3页
China Medicine And Pharmacy
基金
云南省科技计划项目(2010CD173)
关键词
肺栓塞
低分子肝素
抗凝
疗效
Pulmonary embolism
Low-molecular-weight heparin
Anticoagulant
Curative effect
